Abstract
The use of helium in medicine was first described by Barach who treated obstructive lesions of the airways, in 1936. Since then, only scattered reports can be found in the medical literature until the 80s, when interest in helium resurged for the treatment of acute asthma, as deaths from this disease begun to rise. At least theoretically, because of its physical properties, helium should be useful in several obstructive conditions of the airways including upper airway obstruction, croup, post-extubation stridor, asthma attacks, exacerbations of chronic obstructive pulmonary disease (COPD), etc. However, there is not enough evidence to support the systematic use of heliox to treat severe stages or acute exacerbations of COPD in either ventilated or non ventilated patients because there is currently no convincing impact on patient outcome. Therefore, at present, widespread use of heliox cannot be recommended in clinical practice.
Keywords: COPD, expiratory flow limitation, exercise, mechanical ventilation, non-invasive ventilation, helium-oxygen gas mixtures
Current Respiratory Medicine Reviews
Title: Clinical Uses of Heliox Mixtures in Chronic Obstructive Pulmonary Disease
Volume: 5 Issue: 3
Author(s): Nickolaos G. Koulouris, Antonia Koutsoukou and Edgardo D'Angelo
Affiliation:
Keywords: COPD, expiratory flow limitation, exercise, mechanical ventilation, non-invasive ventilation, helium-oxygen gas mixtures
Abstract: The use of helium in medicine was first described by Barach who treated obstructive lesions of the airways, in 1936. Since then, only scattered reports can be found in the medical literature until the 80s, when interest in helium resurged for the treatment of acute asthma, as deaths from this disease begun to rise. At least theoretically, because of its physical properties, helium should be useful in several obstructive conditions of the airways including upper airway obstruction, croup, post-extubation stridor, asthma attacks, exacerbations of chronic obstructive pulmonary disease (COPD), etc. However, there is not enough evidence to support the systematic use of heliox to treat severe stages or acute exacerbations of COPD in either ventilated or non ventilated patients because there is currently no convincing impact on patient outcome. Therefore, at present, widespread use of heliox cannot be recommended in clinical practice.
Export Options
About this article
Cite this article as:
Koulouris G. Nickolaos, Koutsoukou Antonia and D'Angelo Edgardo, Clinical Uses of Heliox Mixtures in Chronic Obstructive Pulmonary Disease, Current Respiratory Medicine Reviews 2009; 5 (3) . https://dx.doi.org/10.2174/157339809788922379
DOI https://dx.doi.org/10.2174/157339809788922379 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Monoclonal Antibody “Gold Rush”
Current Medicinal Chemistry Fractional Exhaled Nitric Oxide and Nanomaterial Exposure in Workplaces
Current Medicinal Chemistry Effects of Extracellular Matrix and Integrin Interactions on Airway Smooth Muscle Phenotype and Function: It Takes Two to Tango!
Current Respiratory Medicine Reviews The Role of Eosinophils in Non-Parasitic Infections
Endocrine, Metabolic & Immune Disorders - Drug Targets Antidiabetic Potential of Fabaceae Family: An Overview
Current Nutrition & Food Science The Ubiquitin-Proteasome System and Proteasome Inhibitors in Central Nervous System Diseases
Cardiovascular & Hematological Disorders-Drug Targets COVID-19 and Autoimmune Diseases: A Systematic Review of Reported Cases
Current Rheumatology Reviews Editorial
Current Respiratory Medicine Reviews Advances in the Development of Bradykinin Receptor Ligands
Current Topics in Medicinal Chemistry HCV and Autoimmunity
Current Pharmaceutical Design Editorial [Hot Topic: An Update on Neurotrophins (Guest Editor: Celia Duarte Cruz)]
Current Neuropharmacology Cytochrome P450 and the Biological Clock in Mammals
Current Drug Metabolism The Use of Leukotriene Modifying Drugs in Asthma and Other Respiratory Diseases
Current Drug Targets - Inflammation & Allergy The Protein Kinase Inhibitor Balanol: Structure – Activity Relationships and Structure-Based Computational Studies
Anti-Cancer Agents in Medicinal Chemistry Germinal and Somatic Trisomy 21 Mosaicism: How Common is it, What are the Implications for Individual Carriers and How Does it Come About?
Current Genomics ADAM Metalloproteinases as Potential Drug Targets
Current Medicinal Chemistry Ultrasound Assisted Faster and Milder Approach to 6H-pyrido[1,2-a] quinazolin-6-imine Derivatives as Potential Inhibitors of PDE4
Letters in Drug Design & Discovery A New Era of Pulmonary Delivery of Nano-antimicrobial Therapeutics to Treat Chronic Pulmonary Infections
Current Pharmaceutical Design Anti-Inflammatory Drugs and Herbs with Special Emphasis on Herbal Medicines for Countering Inflammatory Diseases and Disorders - A Review
Recent Patents on Inflammation & Allergy Drug Discovery The use of Immunoglobulin Therapy in Primary Immunodeficiency Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets